- Danshensu
-
- $31.00
-
2026-08-20
- CAS:76822-21-4
- Purity: 99.44%
- Supply Ability: 10g
- Danshensu
-
-
2024-04-12
- CAS:76822-21-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
|
| | Danshensu Basic information |
| Product Name: | Danshensu | | Synonyms: | (r)-a,3,4-trihydroxybenzenepropanoic acid;Danshensu;dan shen suan a;(R)-2-Hydroxy-3-(3,4-dihydroxyphenyl)propanoic acid;(R)-2-Hydroxy-3-(3,4-dihydroxyphenyl)propionic acid;3-(3,4-Dihydroxyphenyl)-D-lactic acid;β-(3,4-Dihydroxyphenyl)-D-lactic acid;Sodium Danshensu ,98% | | CAS: | 76822-21-4 | | MF: | C9H10O5 | | MW: | 198.17 | | EINECS: | | | Product Categories: | Plant extracts;76822-21-4 | | Mol File: | 76822-21-4.mol |  |
| | Danshensu Chemical Properties |
| Melting point | >210°C (dec.) | | Boiling point | 481.5±40.0 °C(Predicted) | | density | 1.546 | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Water (Slightly) | | form | Solid | | pka | 3.82±0.10(Predicted) | | color | Light Beige | | InChI | InChI=1/C9H10O5/c10-6-2-1-5(3-7(6)11)4-8(12)9(13)14/h1-3,8,10-12H,4H2,(H,13,14)/t8-/s3 | | InChIKey | PAFLSMZLRSPALU-SBYBRXNCNA-N | | SMILES | C(=O)(O)[C@H](O)CC1=CC=C(O)C(O)=C1 |&1:3,r| |
| | Danshensu Usage And Synthesis |
| Chemical Properties | White crystals, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Salvia miltiorrhiza. | | Uses | Danshensu increases production of collagenin Detroit 551 cells and attenuates the α-MSH-stimulated melanin production of B16 cells. Danshensu may be used as active ingredients in would healing, cosmetic treatments or treating hyperpigmentation. | | Definition | ChEBI: (2R)-3-(3,4-dihydroxyphenyl)lactic acid is a (2R)-2-hydroxy monocarboxylic acid that is (R)-lactic acid substituted at position 3 by a 3,4-dihydroxyphenyl group. It is a (2R)-2-hydroxy monocarboxylic acid and a 3-(3,4-dihydroxyphenyl)lactic acid. It is a conjugate acid of a (2R)-3-(3,4-dihydroxyphenyl)lactate. | | in vivo | Danshensu (Dan shen suan A; 25, 50, 100mg/kg; oral administration daily for 7 continuous days or i.v. once) before SARS-CoV-2 S infection dose-dependently alleviates the pathological alterations in mice infected with SARS-CoV-2 S[1].
| Animal Model: | Adult BALB/c mice (male, 6-8 weeks, 20±2g)[1] | | Dosage: | 25, 50, 100mg/kg | | Administration: | Oral administration (daily for 7 continuous days) or i.v. (once) | | Result: | Could prevent SARS-CoV-2 S protein-induced acute lung inflammation.
Ameliorated inflammatory cytokines in serum and lung tissue.
|
|
| | Danshensu Preparation Products And Raw materials |
|